Search Within

Carol A Aghajanian

Formats
  1. Journal Article (325)
  2. Meeting Abstract (284)
  3. Review (3)
  4. Book Section (1)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. Department of Medicine (615)
  2. GDMT, Medicine (615)
  3. Gynecologic Medicine Service (615)
  4. Gynecology Disease Management Team (615)
  5. Solid Tumor Oncology Division (615)
  6. Surgery (229)

More Groups

People
  1. Nadeem Abu-Rustum (126)
  2. Paul Sabbatini (125)
  3. Alexia Iasonos (116)
  4. David Spriggs (105)
  5. Roisin O'Cearbhaill (99)
  6. Martee Hensley (94)

More People

Years
  1. 2025 (24)
  2. 2024 (38)
  3. 2023 (42)
  4. 2022 (45)
  5. 2021 (35)
  6. 2020 (61)

More Years

Publications
  1. Gynecologic Oncology (200)
  2. Journal of Clinical Oncology (150)
  3. International Journal of Gynecological Cancer (57)
  4. Clinical Cancer Research (30)
  5. Annals of Oncology (28)
  6. Cancer (15)

More Publications

Publishers
  1. Elsevier B.V. (204)
  2. American Society of Clinical Oncology (156)
  3. Lippincott Williams & Wilkins (59)
  4. American Association for Cancer Research (54)
  5. Oxford University Press (30)
  6. Elsevier Inc. (21)

More Publishers

Results (615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study
    Meeting Abstract

    Gien, L.; Enserro, D.; Block, M.; Waggoner, S.; Duska, L.; Hendrickson, A. W.; Thaker, P.; Backes, F.; Bottsford-Miller, J.; Muller, C.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Overall survival results from Ariel3: A phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
    Meeting Abstract

    Coleman, R. L.; Oza, A.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.; Clamp, A.; Scambia, G.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Prognosis of isolated tumor cells and the utility of molecular classification in early stage endometrioid endometrial cancer
    Meeting Abstract

    Rios-Doria, E.; Abu-Rustum, N.; Alektiar, K.; Makker, V.; Liu, Y.; Zamarin, D.; Friedman, C.; Aghajanian, C.; Ellenson, L.; Weigelt, B.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • A randomized phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort
    Meeting Abstract

    Okamoto, A.; Kim, J. W.; Yin, R.; Trillsch, F.; Reuss, A.; Aghajanian, C.; Rubio-PeĢrez, M. J.; Vardar, M. A.; Scambia, G.; Floquet, A.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Molecular classification of endometrial carcinomas: A single-institution review
    Meeting Abstract

    Rios-Doria, E.; Abu-Rustum, N.; Leitao, M.; Alektiar, K.; Makker, V.; Liu, Y.; Zamarin, D.; Friedman, C.; Aghajanian, C.; Ellenson, L.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Predicting outcomes in female germ cell patients using a modified International Germ Cell Cancer Collaborative Group classification system to guide management
    Meeting Abstract

    Manning-Geist, B.; Deng, L.; Knezevic, A.; Bromberg, M.; Funt, S.; Zivanovic, O.; Roche, K. L.; Sonoda, Y.; Gardner, G.; Grisham, R.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Safety and immunogenicity of anti PD-L1 (atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: An NRG oncology trial
    Meeting Abstract

    Mayadev, J.; Zamarin, D.; Deng, W.; Lankes, H.; Pesci, G.; Park, K.; Banbury, B.; Sherry, N.; Ghamande, S.; Holman, L.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Risk stratification of stage I grade 3 endometrioid endometrial carcinoma
    Meeting Abstract

    Zammarrelli, W.; Kim, S.; Paula, A. D. C.; Rios-Doria, E.; Zhou, Q.; Alektiar, K.; Aghajanian, C.; Makker, V.; Leitao, M.; Abu-Rustum, N.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Long term survival of GOG 252 'randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/GOG study'
    Meeting Abstract

    Walker, J.; Mark, B.; Moore, K.; Tewari, K.; Thaker, P.; DiSilvestro, P.; Van Le, L.; Guntupalli, S.; Gray, H.; Rose, P.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
    Journal Article

    O'Malley, D. M.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save